Why the study?
What are the updated Korean Heart Rhythm Society recommendations for antithrombotic therapy to prevent stroke in patients with nonvalvular atrial fibrillation?
What are the updated Korean Heart Rhythm Society recommendations for antithrombotic therapy to prevent stroke in patients with nonvalvular atrial fibrillation?
The updated KHRS guidelines emphasize the use of the CHA2DS2-VASc score for risk stratification and preferentially recommend NOACs over warfarin for stroke prevention in nonvalvular atrial fibrillation.
Recommends OAC for nonvalvular AF with CHA2DS2-VASc ≥2; extends prior KHRS guidance by prioritizing NOACs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Byung Chun Jung (2016) conducted a review in Nonvalvular atrial fibrillation. Oral anticoagulants (NOACs or warfarin) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: